New Delaware Chapter 11 Filing – NephroGenex, Inc.
NephroGenex, Inc. (Nasdaq – NRX), an innovator in the development of drugs to treat kidney disease, has filed a chapter 11 petition before the United States Bankruptcy Court for the District of Delaware (Case No. 16-11074). The case has been assigned to the Honorable Kevin Gross. The company has filed a motion to sell substantially all of its assets. The petition (including the list of top 20 creditors), the first day declaration and the docket are available through Kurtzman Carson Consultants. The company has issued a press release regarding its reorganization efforts.
Contact Norman L. Pernick, Nicholas J. Brannick, or David W. Giattino for more information.
As the law continues to evolve on these matters, please note that this article is current as of date and time of publication and may not reflect subsequent developments. The content and interpretation of the issues addressed herein is subject to change. Cole Schotz P.C. disclaims any and all liability with respect to actions taken or not taken based on any or all of the contents of this publication to the fullest extent permitted by law. This is for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Do not act or refrain from acting upon the information contained in this publication without obtaining legal, financial and tax advice. For further information, please do not hesitate to reach out to your firm contact or to any of the attorneys listed in this publication.